Hot topics in antiviral therapy for chronic hepatitis B

( views:, downloads: )
LIU Ke-zhou()
Journal Title:
Volume 1, Issue 03, 2008
Key Word:


  • [1]Liaw YF,Leung N,Kao JH,et al.Asian-Pacific consensus statement on the management of chronichepatitis B:a 2008 update.Hepatoi int,DOI 10.1007/s12072-008-9080-34.
  • [2]Lak AS.Navigating the maze of hepatitis B txeatments.Gastroenterology,2007,132(4):1586-1594.
  • [3]Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a,lamivudine and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med,2005,352(26):2682-2695.
  • [4]Marcellin P,Lau GK.Bonino F,et al.Peginterferon afla-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med,2004,351(12):1206-1217.
  • [5]Marcellin P,Pimtvisuth T,Bruneno M,et al.Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with pegintederon alfa-2a(40KD)with or without lamivudine:results of 4-year foHow-up.J Hepatol,2008,48(Suppl 2):S46(103).
  • [6]Chang TT,Chan YC,Lai CL,et al.Four-year treatment with entecavir results in high proportions of nueleoside-naive HBeAgpositive patients with undetectable HBVDNA:results from studies ETV-022 and-901.Hepatol Int,2008,2(1):A111(FP001).
  • [7]Tenney DJ,Pokomowski KA,Rose RE,et al.Entocavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance.Hepatol Int,2008,2(1):A88-A89(PL02).
  • [8]Takehara T,Hayashi N and Takaguchi K,et al.Efficacy and safety of 3 years treatment with entecavir(ETV)in Japanese nucleoside-naive patients with chronic hepatitis B(CHB).Hepatol Int,2008,2(1):A97-A98(PP007).
  • [9]Izumi N,Kumada H,Toyota J,et al.Efficacy and safety of 3 years treatment with entecavir(ETV)in Lamivudine(LVD)-refractory Japanese chronic hepatitis B(CHB)patients.Hepatol int,2008,2(1):A186(FP127).
  • [10]Mao Y,Zeng M,Yan G,et al.Efficacy and safety of 4 years adefovir dipivoxil 10 mg(ADV)in Chinese HBeAg+ve chronic hepatitis B(CHB).Hepatol Int,2008,2(1):A98(PP009).
  • [11]Jia JD.Liaw YF,Hou J,et al.Telbivudine achieves significantly greater HBeAg semeonversion rates than lamivudine:results of a pooled analysis of patients with genotype B or C chronic hepatitis B.Hepatol Int,2008,2(1):A99(PP011).
  • [12]Marcellin P,Jaeobson I,Habersetzer F,et al.Tenofovir disoproxil fumarate(TDF)for the treatment of HBeAg negative chronic hepatitis B:week 72 TDF data and week 24 adefovir dipivoxil switch data(Study 102).J Hepatol,2008,48(Suppl 2):S26(57).
  • [13]Heathcote J,George J,Gordon S,et al.Tenofovir disoproxil fumarate(TDF)for the treatment of HBeAg positive chronic hepatitis B:week 72 TdF data and week 24 Adefovir dipivoxil switch data(study 103).J Hepatd,2008,48(Suppl 2):S32(72).
  • [14]Buti M,Hadziyannis S,Mathurin P,et al.Tenofovir disoproxil fumarate(TDF)is highly active for treatment of chronic hepatitis B in subjects with cirrhosis.J Hepatol,2008,48(Suppl 2):S33(75).
  • [15]van Bommel F,De Man RA,Stein K,et al.A muhicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfeeted patients with prior nucleos(t)ida analog experience.J Hepatol,2008,48(Suppl 2):S32(73).
  • [16]Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:roadmap for management of patients receiving oral therapy for chronic hepatitis B.Clin Gastroenterol Hepatol,2007,5(8):890-897.
  • [17]Shaw T,Sozzi T,Locamini SA,et al.Combination therapy with nucleos(t)ide analog reverse transcriptase inhibitors(NRTI):using in vitro phenotyping to optimise NRTI combinations for treatment for muhidrug-resistant HBV.J Hepatol,48(Suppl 2):S260(699).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615